Eli Lilly partner BioAge files for US IPO
The company’s experimental drug, azelaprag, is being developed for the treatment of obesity.
About Reuters Health
This author has not written his bio yet.
But we are proud to say that Reuters Health contributed 4468 entries already.
Entries by Reuters Health
African drugmaker Aspen bets on GLP-1 drugs to boost profit
Without naming the company, the company said it has secured a commercial licence for the intellectual property necessary to commercialize GLP-1 drugs – a class of highly effective diabetes and obesity drugs – following the expiry of the originator product patents.
Nvidia-backed Recursion’s shares fall on mixed data for rare disorder drug
The drug, REC-994, was being tested to treat cerebral cavernous malformation, or abnormal collection of small blood vessels that form lesions in the brain, which could cause bleeding in the brain, seizures and paralysis.
Illumina wins Grail battle in blow to EU merger power
U.S. gene sequencing company on Tuesday won its court fight against the European Union’s investigation of its $7.1 billion purchase of cancer diagnostic test maker Grail (GRAL.O), a ruling set to curb Brussels’ merger powers.
US will still pay at least twice as much after negotiating drug prices
The U.S. government’s first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income countries, a Reuters review has found.
Alnylam shares slide after heart drug data fails to impress investors
Vutrisiran was tested in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), where function of the heart muscles is restricted due to the accumulation of irregular proteins.
Emergent Bio’s shares soar as smallpox vaccine gets US approval against mpox
The FDA clearance, announced late on Thursday by the company, makes the vaccine, called ACAM2000, the second approved shot against mpox in the United States after Bavarian Nordic’s (BAVA.CO) Jynneos.
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
Contract drug manufacturer Catalent beat analysts’ estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
BioMarin to reduce global workforce by about 225 employees
The decision comes in the wake of the company’s updated strategy for its hemophilia gene therapy, Roctavian, and the discontinuation of its gene therapy BMN 293 development program.
Neurocrine’s schizophrenia drug meets main goal in mid-stage study
The drug was generally safe and well tolerated at all doses tested in the study, Neurocrine said, adding that it plans to begin late-stage trials early next year.